WHWK
WHWK clinical trials: Whitehawk Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Whitehawk Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 2
- Trials linked
- 2
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
WHWK on the catalyst calendar · WHWK registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 2028Sponsor estimate | NCT07470853A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.Whitehawk Therapeutics, Inc. · PROC | WHWKLeadCPRXCollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
| Oct 2028Sponsor estimate | NCT07444814Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsWhitehawk Therapeutics, Inc. · Endometrial Cancer | WHWKLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 2028Sponsor estimatePhase 1NCT07470853A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.Whitehawk Therapeutics, Inc. · PROCRecruitingWHWKLeadCPRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2028Sponsor estimatePhase 1NCT07444814Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsWhitehawk Therapeutics, Inc. · Endometrial CancerRecruitingWHWKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 2 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner